BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative,...
VYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 in healthy volunteers;...
Trial will evaluate once-daily VYN201 gel in subjects with either active or stable nonsegmental vitiligo Top-line data from the 24-week double-blind portion of the trial expected in mid-2025 ...
Design of Phase 2b trial for VYN201 in nonsegmental vitiligo finalized and on track to begin this quarterPhase 2b trial expected to enroll approximately 160 subjects with either active or stable...
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, announced the clearance of its Investigational New Drug application (IND) by the US Food and Drug Administration for VYN202, an oral BD2-selective BET inhibitor. VYNE plans to initiate a first-in-human phase 1a single ascending dose/multiple ascending dose (“SAD/MAD”) trial in healthy volunteers this quarter and expects to report top line results from the SAD/MAD trial in the second half of this year.
In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic...
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics...
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company), a clinical-stage biopharmaceutical company focused on developing proprietary,...
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company), a clinical-stage biopharmaceutical company developing proprietary, innovative,...